NEWS | BEAM Alliance


BioVersys Receives CARB-X Award of up to US$ 8.92 Million for development of first-in-class stand-alone anti-virulence small molecule drugs – A paradigm shift in AMR therapy

Basel, Switzerland, October 29, 2019. 08:00 CET

CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, opening the door for a paradigm shift in AMR therapy.

BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, announced today, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.

BioVersys is developing new drugs designed to disarm bacteria such as Staphylococcus aureus including MRSA of its virulence determinants including toxins, that cause serious skin infections that can spread to muscles, lungs and other body parts. Molecules of the BV200 series have the potential to be used as stand-alone therapy as well as in combination with antibiotics, thus improving many available antibiotic therapies and supporting stewardship. The most advanced compounds are in Lead Optimization.

Full PR available here